Trump's Comments on Weight-Loss Drug Pricing Impact Pharmaceutical Stocks
President Trump's remarks on reducing prices for weight-loss drugs like Ozempic led to significant stock declines for Novo Nordisk and Eli Lilly.
President Donald Trump announced plans to reduce the cost of popular weight-loss drugs, including Novo Nordisk's Ozempic, to approximately $150 per month. This statement, made during a White House event, led to immediate market reactions, with Novo Nordisk's shares falling by up to 6.4% and Eli Lilly's shares declining by around 4% the following day.
The proposed price reduction is part of the administration's broader initiative to align U.S. drug prices with those in other developed nations, under the "most favored nation" policy. Novo Nordisk confirmed ongoing discussions with the administration regarding this policy.
Dr. Mehmet Oz, Administrator of the Centers for Medicare & Medicaid Services, clarified that negotiations for GLP-1 drugs, which include Ozempic, have not yet commenced. He stated, "We have not negotiated those yet. We're going to be rolling these out over time."
In response to the mounting pressure on drug pricing, Novo Nordisk appointed Greg Miley, a seasoned U.S. pharmaceutical executive, as its new head of corporate affairs. Miley's focus will be on improving relations with the Trump administration, as the U.S. remains Novo's largest market.
The pharmaceutical industry is closely monitoring these developments, as the outcome of the negotiations could significantly impact the pricing and accessibility of weight-loss medications in the U.S. market.